| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $104.2M | +72.0% |
| SG&A Expense | $9.1M | +60.8% |
| Operating Income | -$113.3M | -71.0% |
| Pre-tax Income | -$111.8M | -75.3% |
| Net Income | -$111.8M | -75.3% |
| EPS (Basic) | -$2.83 | -5.2% |
| EPS (Diluted) | -$2.83 | -5.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $22.5M | -26.6% |
| Short-term Investments | $212.6M | +41.8% |
| Current Assets | $244.6M | +28.3% |
| Total Assets | $245.1M | +28.2% |
| Current Liabilities | $31.7M | +123.6% |
| Long-term Debt | $105.1M | +179.8% |
| Total Liabilities | $129.5M | +151.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$83.5M | -55.1% |
| Capital Expenditures | $250K | +155.9% |
| Investing Cash Flow | -$63.1M | -1159.3% |
| Financing Cash Flow | $138.4M | +113.2% |
| Free Cash Flow | -$83.7M | -55.3% |
| Stockholders' Equity |
| $115.6M |
| -17.3% |